2024-01-18T13:21:58-06:00 2023-06-30 390859910 BAKER TILLY US LLP 1 HIGHWOOD DRIVE TEWKSBURY MA 01876 990 2022-07-01 521375827 NATIONAL SCLERODERMA FOUNDATION INC NATI 8007224673 300 ROSEWOOD DRIVE 105 DANVERS MA 01923 MARY J WHEATLEY IOM CAE CHIEF EXECUTIVE OFFICER 8007224673 2024-01-16 1 MARY WHEATLEY IOM CAE 999009999 0 MATTHEW KALIL CPA MBA P01517069 9785575300 2024-01-16 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z MARY J WHEATLEY 300 ROSEWOOD DRIVE 105 DANVERS MA 01923 8832555 0 X WWW.SCLERODERMA.ORG X 1993 IL THE NATIONAL SCLERODERMA FOUNDATION'S MISSION IS TO ADVANCE MEDICAL RESEARCH, PROMOTE DISEASE AWARENESS, AND PROVIDE SUPPORT AND EDUCATION TO PEOPLE WITH SCLERODERMA, THEIR FAMILIES AND SUPPORT NETWORKS. 14 14 33 300 0 0 4462430 6057608 0 0 119037 476604 0 381686 4581467 6915898 2425000 1812000 0 0 2012197 2783041 0 0 645725 1773515 1866701 6210712 6461742 -1629245 454156 11463074 12897422 2913453 3086186 8549621 9811236 X THE NATIONAL SCLERODERMA FOUNDATION'S MISSION IS TO ADVANCE MEDICAL RESEARCH, PROMOTE DISEASE AWARENESS, AND PROVIDE SUPPORT AND EDUCATION TO PEOPLE WITH SCLERODERMA, THEIR FAMILIES AND SUPPORT NETWORKS. 0 0 2573410 A RELENTLESS FORCE IN FINDING A CURE AND IMPROVING THE LIVES OF PEOPLE AFFECTED BY SCLERODERMA, THE NATIONAL SCLERODERMA FOUNDATION ADVANCES MEDICAL RESEARCH, PROMOTES DISEASE AWARENESS, AND PROVIDES SUPPORT AND EDUCATION TO PEOPLE WITH SCLERODERMA, THEIR FAMILIES AND SUPPORT NETWORKS. SUPPORTED BY A NETWORK OF THOUSANDS OF INDIVIDUALS ACROSS THE UNITED STATES, THE FOUNDATION IS THE LEADING NONPROFIT FUNDER OF PEER-REVIEWED RESEARCH TO DISCOVER THE CAUSE, UNDERSTAND THE MECHANISMS, AND OVERCOME SCLERODERMA FOREVER. SUPPORT: THE FOUNDATION SERVES PEOPLE LIVING WITH SCLERODERMA, AS WELL AS THEIR CAREGIVERS AND FAMILY MEMBERS BY PROVIDING ACCESS TO SUPPORT GROUPS. IN THE WAKE OF THE PANDEMIC, THE FOUNDATION PIVOTED FROM IN-PERSON TO VIRTUAL COMMUNITY SUPPORT, ALLOWING FOR MEMBERS OF THE SCLERODERMA COMMUNITY TO CONNECT NO MATTER WHERE THEY WERE IN THE COUNTRY. THIS ALSO ALLOWED FOR THE CREATION OF MORE TARGETED, TOPICAL SUPPORT GROUPS SUCH AS ONE FOR MEN, WHICH MAKE UP JUST 20% OF THE POPULATION IMPACTED BY SCLERODERMA, AND BIPOC, AS WELL AS YOUNG ADULTS. EDUCATION: THE FOUNDATION PROVIDES EDUCATION ABOUT HOW TO LIVE BETTER WITH SCLERODERMA FOR THOSE AFFECTED BY THE DISEASE, AS WELL AS THEIR CAREGIVERS, FAMILIES AND SUPPORT NETWORKS. THE FOUNDATION IS ALSO A CME AND CNE PROVIDER, EDUCATING HEALTHCARE PROVIDERS ABOUT SIGNS AND SYMPTOMS, TIMELY DIAGNOSIS, AND CUTTING-EDGE TREATMENTS AND THERAPIES. THE NATIONAL SCLERODERMA CONFERENCE ATTRACTS MORE THAN 500 PARTICIPANTS ANNUALLY. DUE TO THE ONGOING PANDEMIC, THE FOUNDATION HELD A VIRTUAL CONFERENCE IN FY 2023, WHICH PROVIDED COMMUNITY SUPPORT, WORLD CLASS EDUCATION, AND NETWORKING OPPORTUNITIES FOR THE COMMUNITY VIA WEBINARS. THE WEBINARS OFFERED EDUCATION AND NETWORKING OPPORTUNITIES FOR PEOPLE LIVING WITH SCLERODERMA, CAREGIVERS, FAMILY MEMBERS, AND FRIENDS. IN ADDITION, THE WEBINARS SERVE AS AN EXCELLENT RESOURCE FOR PHYSICIANS AND OTHER HEALTHCARE PROFESSIONALS, WHO ALSO NEED COMPREHENSIVE INFORMATION ABOUT THE DISEASE. 2177271 1812000 RESEARCH:IN FY 2023, THE FOUNDATION MADE A COMMITMENT OF $1.8 MILLION TO FUND RESEARCH. THIS FUNDING AIMS TO STIMULATE AND SUPPORT INVESTIGATIONS INTO BETTER UNDERSTANDING THE MECHANISMS THAT CAUSE THE DISEASE, HOW TO PREVENT AND ACCURATELY DIAGNOSIS AND TREAT THE DISEASE, AND ULTIMATELY FIND A CURE FOR SCLERODERMA. EACH AWARD IS $200,000 SPREAD OVER MULTIPLE YEARS. IN FY 2023, SIX AWARDS WERE TWO-YEAR ESTABLISHED INVESTIGATOR AWARDS, AND THREE AWARDS WERE THREE-YEAR NEW INVESTIGATOR AWARDS. NEW INVESTIGATOR AWARDS ARE INTENDED TO HELP EMERGING SCIENTISTS GATHER SUFFICIENT DATA TO DEMONSTRATE THE VALUE OF THEIR AREA OF INVESTIGATION AND ATTRACT LARGER FUNDING FROM OTHER SOURCES. THE FOUNDATION'S PEER REVIEWED RESEARCH GRANTS PROGRAM PRIORITIZES SCIENTIFIC MERIT AND IS ADMINISTERED BY THE FOUNDATION'S RESEARCH COMMITTEE. THIS COMMITTEE, COMPOSED OF SCLERODERMA EXPERTS FROM ACROSS THE COUNTRY, MAKES FUNDING RECOMMENDATIONS TO THE BOARD OF DIRECTORS ANNUALLY AFTER A RIGOROUS PEER REVIEW PROCESS.THE PEER-REVIEW RESEARCH COMMITTEE IS COMPOSED OF HIGHLY RESPECTED SCIENTIFIC EXPERTS WHO REVIEW, CRITIQUE, AND RANK ALL APPLICATIONS BASED ON THE NATIONAL INSTITUTES OF HEALTH'S RANKING SYSTEM. ONLY PROJECTS OF SIGNIFICANT SCIENTIFIC MERIT ARE FUNDED. EACH GRANT APPLICATION CONTAINS VERY SPECIFIC ELIGIBILITY AND REVIEW CRITERIA. DETAILS REGARDING THESE REQUIREMENTS ARE AVAILABLE AT WWW.SCLERODERMA.ORG. ALL APPLICATIONS UNDERGO RIGOROUS PEER REVIEW AND ARE SCORED AND RANKED ACCORDING TO THE REVIEW CRITERIA AND OVERALL MERIT OF THE PROPOSAL. PEER REVIEW RANKINGS ARE SENT TO THE FOUNDATION'S RESEARCH COMMITTEE FOR QUALIFICATION BEFORE BEING PRESENTED TO THE FOUNDATION BOARD OF DIRECTORS FOR FINAL APPROVAL OF FUNDING. AFTER THE AWARDS ARE MADE, ALL RECIPIENTS ARE REQUIRED TO COMPLETE FUNDING CONTRACTS WITH INSTITUTIONAL SIGN-OFF AND MUST ALSO SUBMIT ANNUAL REPORTS ON THEIR PROGRESS. ALL REPORTS ARE REVIEWED BY THE FOUNDATION'S RESEARCH COMMITTEE TO ENSURE COMPLIANCE WITH PROGRAMMATIC, SCIENTIFIC, AND FISCAL AND ADMINISTRATIVE POLICES AND REQUIREMENTS. 4750681 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 17 0 1 33 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI NV X X THE ORGANIZATION 8007224673 300 ROSEWOOD DRIVE 105 DANVERS MA 01923 COS MALLOZZI DIRECTOR 2.00 X 0 0 0 COURTNEY CALIENDO DIRECTOR 2.00 X 0 0 0 CHRISTINA LOCCKE DIRECTOR 2.00 X 0 0 0 MARY BLADES DIRECTOR 2.00 X 0 0 0 JEANNE THEISSEN DIRECTOR 2.00 X 0 0 0 MARK OROZCO III MBA DIRECTOR 2.00 X 0 0 0 LINDA BORNSTEIN BAUM OD DIRECTOR 2.00 X 0 0 0 MARCIA WALKER DIRECTOR 2.00 X 0 0 0 ZEBA HYDER DIRECTOR 2.00 X 0 0 0 MICHAEL PURSEL DIRECTOR 2.00 X 0 0 0 KEVIN BOYANOWSKI CHAIR 2.00 X X 0 0 0 CAROL FEGHALI-BOSTWICK PH D VICE CHAIR 2.00 X X 0 0 0 MIKE LEVENGOOD ESQ SECRETARY 2.00 X X 0 0 0 CYNDY BESSELIEVRE CPA TREASURER 2.00 X X 0 0 0 MARY J WHEATLEY CEO 40.00 X 226252 0 17160 MICHAEL B HYDE COO/CFO 40.00 X 150589 0 31671 376841 0 48831 2 0 1 0 MARKSTEIN CONSULTING LLC 1801 FIFTH AVENUE SUITE 200 BIRMINGHAM AL 35203 STRATEGY & COMMUNICATIONS 116415 1 850362 5207246 6057608 203947 203947 2046768 1774111 272657 272657 272657 142546 850362 142546 0 RETURNED GRANT AWARDS 900099 381686 381686 381686 6915898 0 0 858290 1600000 1600000 12000 12000 200000 200000 454933 150712 278236 25985 1796899 1312560 332450 151889 32384 24924 4629 2831 295373 214333 55378 25662 203452 134278 52898 16276 44927 289 44638 44000 44000 44153 44153 435198 346560 88638 11472 6949 2125 2398 176921 69939 17232 89750 326484 195890 65297 65297 216633 135119 39547 41967 127272 82972 22150 22150 140626 111068 10365 19193 220 220 24280 14568 4856 4856 78906 47344 15781 15781 FEES AND LICENSES 176586 89166 30706 56714 OUTREACH 19023 1790 895 16338 6461742 4750681 1065336 645725 2683332 2257990 635411 270820 185646 348601 259947 228239 29987 31708 7887043 9588217 41655 400086 11463074 12897422 208675 315680 2620835 2416673 4529 134975 79414 218858 2913453 3086186 X 6893709 7687928 1655912 2123308 8549621 9811236 11463074 12897422 454156 807459 0 X X 0 1 X 1 0 X 4326448 3405450 3721793 4462430 6057608 21973729 4326448 3405450 3721793 4462430 6057608 21973729 1732619 20241110 175015 180407 167751 175431 203947 902551 22876280 625408 0.88480 0.87220 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1655912 395455 159524 87583 2123308 1881204 -155307 69985 1655912 1658720 293349 70865 1881204 1627038 31682 101713 101713 1658720 1662877 115953 151792 1627038 1.00000 0 0 21166 17218 3948 151753 130228 21525 87028 80793 6235 31708 OPERATING LEASE LIABILITIES 218858 218858 X 7679204 807459 807459 6871745 44153 44153 6915898 6417589 0 6417589 44153 44153 6461742 PART V, LINE 4: THE ENDOWMENT CONSISTS OF FUNDS RESTRICTED IN PERPETUITY ESTABLISHED IN 2007 AND BOARD DESIGNATED ENDOWMENT FUNDS. THE ENDOWMENT IS TO SUPPORT SCLERODERMA RESEARCH . PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON TRADE OR BUSINESS PROFITS GENERATED BY ACTIVITIES RELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. THE ORGANIZATION MAY BE SUBJECT TO FEDERAL AND STATE INCOME TAXES FOR PROFITS GENERATED FROM TRADE OR BUSINESS ACTIVITIES UNRELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. AS OF JUNE 30, 2023, MANAGEMENT BELIEVES THAT THE ORGANIZATION HAS NOT GENERATED ANY UNRELATED BUSINESS TAXABLE INCOME. THE ORGANIZATION ASSESSES THE RECORDING OF UNCERTAIN TAX POSITIONS BY EVALUATING THE MINIMUM RECOGNITION THRESHOLD AND MEASUREMENT REQUIREMENTS A TAX POSITION MUST MEET BEFORE BEING RECOGNIZED AS A BENEFIT IN THE FINANCIAL STATEMENTS. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ACCRUED ON ANY UNCERTAIN TAX POSITIONS AS A COMPONENT OF INCOME TAX EXPENSE, IF ANY, IN ITS STATEMENT OF ACTIVITIES. THE ORGANIZATION HAS NOT RECOGNIZED ANY LIABILITIES FOR UNCERTAIN TAX POSITIONS OR UNRECOGNIZED BENEFITS AS OF JUNE 30, 2023. THE ORGANIZATION DOES NOT EXPECT ANY MATERIAL CHANGE IN UNCERTAIN TAX BENEFITS WITHIN THE NEXT 12 MONTHS. 1 NORTH AMERICA 0 0 GRANT AWARD RESEARCH 200000 0 0 0 0 0 0 200000 0 200000 NORTH AMERICA RESEARCH GRANT 200000 CHECK PAYMENT 0 1 0 0 0 0 0 0 0 PART I, LINE 2: THE FOUNDATION IS THE LEADING NONPROFIT FUNDING SCLERODERMA RESEARCH IN THE UNITED STATES. THROUGH THIS PROGRAM, THE FOUNDATION IS COMMITTED TO DISCOVERING THE CAUSE OF THIS DISEASE, UNDERSTANDING THE MECHANISMS BEHIND IT, AND OVERCOMING SCLERODERMA FOREVER. SINCE ITS INCEPTION, THE FOUNDATION HAS COMMITTED $30 MILLION TO THIS MISSION PRIORITY. THROUGH ITS PEER REVIEWED RESEARCH GRANTS PROGRAM, THE NATIONAL SCLERODERMA FOUNDATION FOSTERS THE DEVELOPMENT OF INNOVATIVE, HIGH-QUALITY RESEARCH BY NEW AND ESTABLISHED INVESTIGATORS IN FIELDS RELATED TO SCLERODERMA. TO THAT END, THE FOUNDATION OFFERS TWO DISTINCT RESEARCH GRANTS: NATIONAL SCLERODERMA FOUNDATION NEW INVESTIGATOR GRANT AND THE NATIONAL SCLERODERMA FOUNDATION ESTABLISHED INVESTIGATOR GRANT. EACH GRANT APPLICATION DETAILS SPECIFIC ELIGIBILITY AND REVIEW CRITERIA (DETAILS REGARDING THESE REQUIREMENTS ARE AVAILABLE AT WWW.SCLERODERMA.ORG). ALL APPLICATIONS UNDERGO A RIGOROUS PEER REVIEW PROCESS COMPARABLE TO THAT OF THE NIH. THE FOUNDATION'S PEER REVIEWED RESEARCH COMMITTEE IS COMPRISED OF MEDICAL AND RESEARCH EXPERTS FROM ACROSS THE UNITED STATES, WHO USE THE SAME MERIT-BASED SCORING SYSTEM AS THE NATIONAL INSTITUTES OF HEALTH. EACH APPLICATION IS CRITIQUED, SCORED AND RANKED ACCORDING TO THE REVIEW CRITERIA AND OVERALL MERIT OF THE PROPOSED PROJECT. ONCE THE STUDY SECTION HAS REVIEWED, DISCUSSED AND RANKED THE FINAL SLATE, THE COMMITTEE ON RESEARCH PUTS FORTH FUNDING RECOMMENDATIONS TO THE BOARD OF DIRECTORS FOR FINAL APPROVAL. PENDING NOTICE OF AWARD, EACH RECIPIENT IS REQUIRED TO COMPLETE A FUNDING CONTRACT SIGNED BY THEIR SPONSORING ORGANIZATION COMMITTING TO COMPLETE THE PROJECT WITHIN A SPECIFIED PERIOD OF TIME, AND WITH NO SCIENTIFIC OR BUDGETARY OVERLAP. RECIPIENTS MUST ALSO SUBMIT ANNUAL PROGRESS REPORTS AND FINANCIAL RECONCILIATIONS, AND COMPLY WITH FOUNDATION POLICIES. PART III ACCOUNTING METHOD: FOOD FIGHT - ROCKY MOUNTAIN 86614 74179 12435 12435 DENVER CO STEPPING OUT WALK 71637 61352 10285 10285 45 834657 714831 119826 119826 992908 850362 142546 142546 142546 0 1 BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON ATTN ACCOUNTS PAYABLE 1201 NINTH AVENUE SEATTLE WA 98101 910653422 501(C)3 200000 0 RESEARCH BOSTON CHILDRENS HOSPITAL ATTN RESEARCH FINANCE PO BOX 414413 BOSTON MA 02241 042774441 501(C)3 200000 0 RESEARCH BOSTON UNIVERSITY TRUSTEES OF BOSTON UNIVERSITY UNIVERSITY GRANTS RECEIVABLES PO BO NEW YORK NH 10087 042103547 501(C)3 200000 0 RESEARCH BOSTON UNIVERSITY TRUSTEES OF BOSTON UNIVERSITY GRANTS RECEIVABLES PO BOX 28763 NEW YORK NY 10087 042103547 501(C)3 200000 0 RESEARCH HACKENSACK UNIVERSITY MEDICAL CENTER HMH HOSPITALS CORPORATION LOCKBOX 7360 PO BOX 95000 PHILADELPHA PA 19195 221487576 501(C)3 200000 0 RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 1 SOUTH PARK CIRCLE MUSC-RESEARCH SPONSORED PROGRAM BUILDING 1 SUITE CHARLESTON SC 29407 576000722 501(C)3 200000 0 RESEARCH UNIVERSITY OF MINNESOTA REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957PO BOX 1450 MINNEAPOLIS MN 55485 416007513 501(C)3 200000 0 RESEARCH FNIH BIOMARKERS CONSORTIUM PROJECT C/O ROSEWOOD DRIVE 105 DANVERS MA 01923 521986675 501(C)3 200000 0 RESEARCH 7 0 PRE-DOCTORAL SUMMER FELLOWSHIP AWARDS- $2,000 PER RECIPIENT 6 12000 0 PART I, LINE 2: THE FOUNDATION IS THE LEADING NONPROFIT FUNDING SCLERODERMA RESEARCH IN THE UNITED STATES. THROUGH THIS PROGRAM, THE FOUNDATION IS COMMITTED TO DISCOVERING THE CAUSE OF THIS DISEASE, UNDERSTANDING THE MECHANISMS BEHIND IT, AND OVERCOMING SCLERODERMA FOREVER. SINCE ITS INCEPTION, THE FOUNDATION HAS COMMITTED $30 MILLION TO THIS MISSION PRIORITY. THROUGH ITS PEER REVIEWED RESEARCH GRANTS PROGRAM, THE NATIONAL SCLERODERMA FOUNDATION FOSTERS THE DEVELOPMENT OF INNOVATIVE, HIGH-QUALITY RESEARCH BY NEW AND ESTABLISHED INVESTIGATORS IN FIELDS RELATED TO SCLERODERMA. TO THAT END, THE FOUNDATION OFFERS TWO DISTINCT RESEARCH GRANTS: NATIONAL SCLERODERMA FOUNDATION NEW INVESTIGATOR GRANT AND THE NATIONAL SCLERODERMA FOUNDATION ESTABLISHED INVESTIGATOR GRANT. EACH GRANT APPLICATION DETAILS SPECIFIC ELIGIBILITY AND REVIEW CRITERIA (DETAILS REGARDING THESE REQUIREMENTS ARE AVAILABLE AT WWW.SCLERODERMA.ORG). ALL APPLICATIONS UNDERGO A RIGOROUS PEER REVIEW PROCESS COMPARABLE TO THAT OF THE NIH. THE FOUNDATION'S PEER REVIEWED RESEARCH COMMITTEE IS COMPRISED OF MEDICAL AND RESEARCH EXPERTS FROM ACROSS THE UNITED STATES, WHO USE THE SAME MERIT-BASED SCORING SYSTEM AS THE NATIONAL INSTITUTES OF HEALTH. EACH APPLICATION IS CRITIQUED, SCORED AND RANKED ACCORDING TO THE REVIEW CRITERIA AND OVERALL MERIT OF THE PROPOSED PROJECT. ONCE THE STUDY SECTION HAS REVIEWED, DISCUSSED AND RANKED THE FINAL SLATE, THE COMMITTEE ON RESEARCH PUTS FORTH FUNDING RECOMMENDATIONS TO THE BOARD OF DIRECTORS FOR FINAL APPROVAL. PENDING NOTICE OF AWARD, EACH RECIPIENT IS REQUIRED TO COMPLETE A FUNDING CONTRACT SIGNED BY THEIR SPONSORING ORGANIZATION COMMITTING TO COMPLETE THE PROJECT WITHIN A SPECIFIED PERIOD OF TIME, AND WITH NO SCIENTIFIC OR BUDGETARY OVERLAP. RECIPIENTS MUST ALSO SUBMIT ANNUAL PROGRESS REPORTS AND FINANCIAL RECONCILIATIONS, AND COMPLY WITH FOUNDATION POLICIES. X 0 0 0 0 0 0 0 0 0 MARY J WHEATLEY CEO 226252 0 0 0 0 0 6421 0 10739 0 243412 0 0 0 MICHAEL B HYDE COO/CFO 150589 0 0 0 0 0 4644 0 27027 0 182260 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO FILING, THE FORM 990 IS GIVEN TO ALL BOARD MEMBERS FOR REVIEW. ANY QUESTIONS ARE ANSWERED BY EITHER MANGEMENT OF THE ORGANIZATION OR THE INDEPENDENT AUDITOR. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS SUBMIT ANNUAL DISCLOSURE STATEMENTS, WHICH ARE THEN REVIEWED BY THE COMMITTEE ON CORPORATE GOVERNANCE AND NOMINATIONS AND FILED WITH LEGAL COUNSEL. ANY MEMBER WHO GIVES NOTICE OF POTENTIAL CONFLICT IS ADVISED TO ABSTAIN FROM PARTICIPATING IN ANY ITEM OF BUSINESS RELATED TO THAT CONFLICT(S) WHICH MAY COME BEFORE THE BOARD. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS OF THE ORGANIZATION VOTES AND APPROVES THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER (CEO). THE CEO ESTABLISHES THE COMPENSATION FOR ALL OTHER EMPLOYEES OF THE ORGANIZATION. NO BOARD MEMBERS ARE COMPENSATED. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT FOR THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED DURING THE YEAR.